The effect of TJ-28 (Eppikajutsuto) on the prevention of hand-foot syndrome using Capecitabine for colorectal cancer: The Yokohama Clinical Oncology Group Study (YCOG1102)
ConclusionCapecitabine-associated HFS was not markedly prevented by TJ-28 compared with pyridoxine. However, TJ-28 might support the continuation of chemotherapy with capecitabine. Further studies are warranted to clarify the benefits of TJ-28.
Source: Indian Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Arthritis | Cancer | Cancer & Oncology | Chemotherapy | Colorectal Cancer | Eczema | Gastroenterology | India Health | Liver | Oral Cancer | Rheumatoid Arthritis | Rheumatology | Study | Toxicology | Urology & Nephrology | Vitamin B6 | Xeloda